- For the Russian Federation: Males and females aged 12 to 14 months or 16 to 23 months on the day of the first study visit (eligible for enrollment to MenACYW conjugate vaccine group) or 15 to 23 months on the day of the first study visit (eligible for enrollment to the MenACYW conjugate vaccine+PCV13 group or the PCV13 group)